PAR04-122, Extramural Research Facilities Improvement P*

PAR04-122，校外研究设施改进 P*

• 批准号: 7000731
• 负责人: RAPHAEL E. POLLOCK
• 金额: $ 800万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-10-20 至 2013-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7000731
• 关键词: Extramural Activities; research facility

DESCRIPTION (provided by applicant): The major goal of the Biomedical Research Tower (BRT) is to create a multidisciplinary biomedical research and education center for The Ohio State University Medical Center (OSUMC) that will be a centerpiece of a dramatically enhanced health sciences campus. Integral to the University's Academic Plan for becoming a top public research institution, the BRT will greatly advance the academic mission of the University while bringing enormous value in improved health care, advanced technology, and economic growth to the State of Ohio. The specific renovation project being proposed is for the "buildout" of a floor of the BRT (approximately 24,000 asf) to centralize and support one of the fastest growing and developing areas of cancer research, the Experimental Therapeutics Program (ETP) of The Ohio State University Comprehensive Cancer Center (OSUCCC). The ETP plays a critical role in the discovery and development of new cancer therapies. A strong tradition of therapeutic research has been the focus of our nationally recognized program enabling both the design and conduct of trials at the initial interface between basic and clinical research for "first in human" studies. The explosion in knowledge of molecular genetics has had a profound impact on understanding both efficacy and toxicity assessments in patients on experimental clinical trials. These remarkable advances have paved the way for incorporating pharmacodynamics, pharmacokinetics, and pharmacogenomics investigations into the evaluation of these newer therapies. Validation of the scientific "proof of principle" underlying each new therapeutic approach has been mandated. The requested federal funding will enable our institution to bring highly trained experts in drug discovery and development into close proximity, and thus improve the scientific process of discovering new therapeutic approaches for patients with cancer. Furthermore, the proposed construction of a dedicated floor for experimental therapeutics within the BRT will facilitate a planned expansion of faculty recruitment targeting specific areas of solid tumor oncology. Our Comprehensive Cancer Center in conjunction with the College of Medicine has outlined a plan for recruitment of at least twelve new investigators. The specific focus of the recruitments will include: a Director of Gastrointestinal Malignancy; a Director of Head and Neck Medical Oncology; a senior physician scientist with expertise in multiple myeloma; three junior faculty investigators in solid tumor oncology; and two additional clinical investigators in hematological malignancies (leukemia and lymphoma). In addition, the recruitment plan calls for three additional basic scientists (PhD's) with a senior basic scientist to direct and coordinate phase I activities in the James Cancer Hospital. Several of these individuals have already been identified, and have just re-located to The Ohio State University. The success in recruitment will necessitate identification of new space because the existing peer reviewed research funding of the established investigators also continues to grow. Thus, the expansion of new space in the BRT will both enhance research productivity, and allow the full recruitment plan to be executed over the next three years. While the initial plans call for the recruitment of specific investigators into Oncology, there is a long-term initiative, OSU Project Cancer, designed to support a larger expansion, including the recruitment of 90 individuals, with a major emphasis being the development of Solid Tumor Oncology. The development of the ETP at Ohio State will enhance access to outstanding patient care, promising and innovative research protocols, and exemplary teaching. Recruiting top caliber faculty to fill voids in the Division of Hematology and Medical Oncology in the areas of head and neck cancer, lung cancer, gastrointestinal cancers, and genitourinary malignancies will enable our physicians to provide disease specific expertise in therapeutics that will have a national impact on fatal diseases. In this manner, Ohio State will also be a beacon for training the next generation of scientists committed to experimental therapeutics. This cadre of multi-disciplinary experts will spread the scientific approach for translational research in cancer treatment. With a significant academic list of accomplishments in a focused specialty, our cancer program will be recognized as one of the ten best in the United States.

描述(由申请人提供)： 生物医学研究塔(BRT)的主要目标是为俄亥俄州立大学医学中心(OSUMC)创建一个多学科生物医学研究和教育中心，该中心将成为一个显著增强的健康科学校园的中心。作为该大学成为顶级公共研究机构的学术计划的组成部分，BRT将极大地推动该大学的学术使命，同时为俄亥俄州带来改善医疗保健、先进技术和经济增长的巨大价值。正在提议的具体翻新项目是对BRT(约24,000 ASF)的一层楼进行“扩建”，以集中和支持癌症研究中增长最快和发展最快的领域之一--俄亥俄州立大学综合癌症中心(OSUCCC)的实验治疗计划(ETP)。 ETP在发现和开发新的癌症治疗方法方面发挥着关键作用。治疗研究的深厚传统一直是我们国家认可的计划的重点，该计划允许在基础研究和临床研究之间的初始界面设计和实施试验，以进行“人类第一”研究。分子遗传学知识的爆炸性增长对理解实验性临床试验中患者的疗效和毒性评估产生了深远的影响。这些显著的进展为将药效学、药代动力学和药物基因组学研究纳入这些新疗法的评估铺平了道路。对每一种新的治疗方法背后的科学“原则证据”的验证已被授权。申请的联邦资金将使我们的机构能够将训练有素的药物发现和开发专家拉近距离，从而改进为癌症患者发现新治疗方法的科学进程。 此外，拟议在BRT内建造一个专门用于实验治疗的楼层，将有助于有计划地扩大针对实体肿瘤肿瘤学特定领域的教师招聘。我们的综合癌症中心与医学院合作，概述了一项招募至少12名新调查人员的计划。招聘的具体重点将包括：一名胃肠道恶性肿瘤主任；一名头颈内科肿瘤科主任；一名具有多发性骨髓瘤专业知识的高级内科科学家；三名实体肿瘤系初级研究员；以及另外两名血液恶性肿瘤(白血病和淋巴瘤)临床调查员。此外，招聘计划要求增加三名基础科学家(博士)和一名资深基础科学家，以指导和协调詹姆斯癌症医院的第一阶段活动。其中几个人的身份已经确定，并刚刚被重新安置到俄亥俄州立大学。招聘的成功将需要确定新的空间，因为现有同行审查的现有研究经费也在继续增长。因此，BRT的新空间的扩大既可以提高研究效率，又可以在未来三年内执行全面的招聘计划。虽然最初的计划要求在肿瘤学领域招募特定的调查人员，但有一个长期倡议，即OSU癌症项目，旨在支持更大规模的扩张，包括招募90人，主要重点是发展实体肿瘤肿瘤学。 俄亥俄州立大学ETP的发展将加强获得出色的患者护理、有前途的创新研究方案和模范教学的机会。招募顶尖教员填补血液和内科肿瘤科在头颈癌、肺癌、胃肠癌和泌尿生殖系统恶性肿瘤领域的空缺，将使我们的医生能够提供针对疾病的治疗专业知识，这将对全国致命疾病产生影响。通过这种方式，俄亥俄州立大学也将成为培养致力于实验疗法的下一代科学家的指路明灯。这支由多学科专家组成的团队将传播癌症治疗中转化性研究的科学方法。凭借在某一重点专业取得的重大学术成就，我们的癌症项目将被公认为美国十大最佳项目之一。